Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Sao Paulo Med J ; 137(5): 438-445, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31939569

RESUMO

BACKGROUND: Management of rectal cancer has become more complex with multimodality therapy (neoadjuvant chemoradiotherapy and surgery) and this has led to the need to organize multidisciplinary teams. The aim of this study was to report on the planning, implementation and evaluation of an integrated care pathway for neoadjuvant treatment of middle and lower rectal cancer. DESIGN AND SETTING: This was a cross-sectional post-implementation study that was carried out at a public university cancer center. METHODS: The Framework for Program Evaluation in Public Health of the Centers for Disease Control and Prevention (CDC) was used to identify resources and activities; link results from activities and outcomes with expected goals; and originate indicators and outcome measurements. RESULTS: The logic model identified four activities: stakeholders' engagement, clinical pathway development, information technology improvements and training programs; and three categories of outcomes: access to care, effectiveness and organizational outcomes. The measurements involved 218 patients, among whom 66.3% had their first consultation within 15 days after admission; 75.2% underwent surgery < 14 weeks after the end of neoadjuvant treatment and 72.7% completed the treatment in < 189 days. There was 100% adherence to the protocol for the regimen of 5-fluorouracil and leucovorin. CONCLUSIONS: The logic model was useful for evaluating the implementation of the integrated care pathways and for identifying measurements to be made in future outcome studies.


Assuntos
Procedimentos Clínicos/normas , Terapia Neoadjuvante/normas , Avaliação de Programas e Projetos de Saúde/métodos , Neoplasias Retais/terapia , Protocolos de Quimioterapia Combinada Antineoplásica , Brasil , Terapia Combinada , Estudos Transversais , Fluoruracila/uso terapêutico , Humanos , Leucovorina/uso terapêutico , Modelos Logísticos , Avaliação de Programas e Projetos de Saúde/normas , Neoplasias Retais/tratamento farmacológico , Neoplasias Retais/cirurgia
2.
J Palliat Med ; 21(5): 659-664, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29368987

RESUMO

BACKGROUND: Integrating palliative care into standard oncology care has been recommended for cancer patients. Early palliative care is associated with less aggressive treatment at the end of life. OBJECTIVE: To describe cancer patients receiving palliative care in Brazil, determining the time from entry into palliative care to death, and investigating whether late referral to palliative care is associated with aggressive end-of-life treatment. DESIGN: This was a cross-sectional study of cancer patients receiving palliative care in Brazil. SETTING/SUBJECTS: Subjects were 2985 cancer patients ≥18 years of age who received at least two palliative care visits at the São Paulo State Cancer Institute, in the city of São Paulo, Brazil, and died between 2010 and 2013. MEASUREMENTS: We evaluated the time from the first palliative care consult to death, stratifying cases by the timing of entry into palliative care (≥3 or <3 months before death). The associations between early palliative care and indicators of aggressive treatment were assessed by Pearson's chi-square test and Fisher's exact test. RESULTS: The overall median time between entry into palliative care and death was 34 days (mean, 72 days) and was significantly shorter in 2013 than in 2010 (p < 0.001). The number of emergency department visits was significantly lower among the patients who entered palliative care earlier (p < 0.001). CONCLUSIONS: Among cancer patients in Brazil, late referral to palliative care is common. Patients who enter palliative care earlier appear to receive less aggressive end-of-life treatment.


Assuntos
Enfermagem de Cuidados Paliativos na Terminalidade da Vida/organização & administração , Neoplasias/enfermagem , Cuidados Paliativos/organização & administração , Assistência Terminal/organização & administração , Tempo para o Tratamento , Idoso , Brasil , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
3.
Arq. bras. oftalmol ; 62(1): 78-81, jan.-fev. 1999. ilus, graf
Artigo em Português | LILACS | ID: lil-251231

RESUMO

Neoplasias fibro-histiocíticas da conjuntiva säo raras. O fibroxantoma atípico é considerado uma variante superficial do fibro-histiocitoma maligno (FHM). Relatamos o primeiro caso da literatura nacional em uma mulher de 78 anos. Os aspectos clínicos e histopatológicos desta neoplasia säo discutidos.


Assuntos
Humanos , Feminino , Idoso , Neoplasias da Túnica Conjuntiva/diagnóstico , Histiocitoma Fibroso Benigno
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA